Education
About Us
Working with TipRanks
Follow Us
Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
SRRK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.76 - $46.98
Previous CloseN/A
Volume133.12K
Average Volume (3M)1.50M
Market Cap
$3.11B
Enterprise Value$3.68B
Total Cash (Recent Filing)-$28.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.89
Next Earnings
May 08, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.57
Shares Outstanding94,860,245
10 Day Avg. Volume1,256,607
30 Day Avg. Volume1,499,522
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-14.72
Forecast
1Y Price Target
$50.17Price Target Upside52.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Scholar Rock Holding News
PremiumCompany Announcements
Scholar Rock Appoints David Hallal as New CEO
PremiumCompany Announcements
Scholar Rock Holding Appoints Interim Financial Officer
PremiumCompany Announcements
Scholar Rock’s Earnings Call Highlights SMA Progress and Obesity Challenges
---
Bulls Say, Bears Say
Bulls Say
Leadership And ManagementScholar Rock announced several key C-suite appointments, including a new Chief Executive Officer, which may bring fresh strategic insights and leadership to the company.
Market PotentialEx-US revenues are likely to represent approximately two-thirds of the peak apitegromab revenue guidance, indicating strong international market potential.
Regulatory And Commercial OutlookWith the likely regulatory approval and robust commercial uptake in both the US and EU given the previously reported stat-sig benefits in HFMSE score and limited to no competition, we see upside to SRRK shares and M&A potential.
Bears Say
CompetitionThe commercial opportunity for muscle preserving agents remains underappreciated.
Financial And Market RisksResults support the mechanistic rationale for apitegromab and SRK-439 in obesity, but the market's response to the proof of concept data remains uncertain.
Financial StrategySRRK has increased its credit line to $150MM, which includes access to funds upon FDA approval and hitting commercial milestones, but reliance on additional funding sources may pose financial risks.
---
Ownership Overview
Currently, No data available
---
SRRK FAQ
What was Scholar Rock Holding Corp’s price range in the past 12 months?
Scholar Rock Holding Corp lowest stock price was $6.76 and its highest was $46.98 in the past 12 months.
What is Scholar Rock Holding Corp’s market cap?
Scholar Rock Holding Corp’s market cap is $3.11B.
When is Scholar Rock Holding Corp’s upcoming earnings report date?
Scholar Rock Holding Corp’s upcoming earnings report date is May 08, 2025 which is in 4 days.
How were Scholar Rock Holding Corp’s earnings last quarter?
Scholar Rock Holding Corp released its earnings results on Feb 27, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.601 by -$0.019.
Is Scholar Rock Holding Corp overvalued?
According to Wall Street analysts Scholar Rock Holding Corp’s price is currently Undervalued.
Does Scholar Rock Holding Corp pay dividends?
Scholar Rock Holding Corp does not currently pay dividends.
What is Scholar Rock Holding Corp’s EPS estimate?
Scholar Rock Holding Corp’s EPS estimate is -0.66.
How many shares outstanding does Scholar Rock Holding Corp have?
Scholar Rock Holding Corp has 94,860,245 shares outstanding.
What happened to Scholar Rock Holding Corp’s price movement after its last earnings report?
Scholar Rock Holding Corp reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.601. Following the earnings report the stock price went down -2.863%.
Which hedge fund is a major shareholder of Scholar Rock Holding Corp?
Currently, no hedge funds are holding shares in SRRK
---
Scholar Rock Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.17 (52.45% Upside)
$50.17 (52.45% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $66.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.98%
12-Months-Change
Fundamentals
Return on Equity
-82.95%
Trailing 12-Months
Asset Growth
52.69%
Trailing 12-Months
Company Description
Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
---
SRRK Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive outlook for Scholar Rock, with significant progress in its SMA program and commercial preparations for apitegromab. However, there are challenges and uncertainties in the obesity program related to regulatory expectations and the competitive landscape.Read More>---
SRRK Stock 12 Month Forecast
Average Price Target
$50.17
▲(52.45% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Viking Therapeutics
―
Apellis Pharmaceuticals
―
Crinetics Pharmaceuticals
―
Immunovant
―
---